Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886715 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,110
- Enrollment target
NCT02886715 is a Phase 3 study that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 1,110 participants.
The verdict
NCT02886715, a Phase 3 study, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,110 participants
- Enrollment target
Study Summary
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
Interventions
- DRUG Placebo
- DRUG Tazarotene Cream 0.1%
- DRUG Tazorac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,110 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02886715
The ClinicalTrials.gov registry entry for NCT02886715 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fougera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02886715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02886715 about?
NCT02886715 is a clinical study titled "A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris". A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
What is the current status of trial NCT02886715?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,110 participants. The study started on 2016-09-21. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT02886715?
The interventions under investigation include: Placebo (DRUG), Tazarotene Cream 0.1% (DRUG), Tazorac® (DRUG).
Who is sponsoring clinical trial NCT02886715?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.